Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Otonomy	Adamis Pharmaceuticals	Anixa Biosciences	Minerva Neurosciences	Zynerba Pharmaceuticals
Symbol	NASDAQ:OTIC	NASDAQ:ADMP	NASDAQ:ANIX	NASDAQ:NERV	NASDAQ:ZYNE
Price Information
Current Price	$2.33	$0.75	$4.31	$2.57	$4.19
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.3	1.4	1.6	1.3
Analysis Score	3.5	3.0	3.5	3.3	3.4
Community Score	2.6	3.0	2.9	2.8	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.8	1.7	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$8.30	$1.25	$11.00	$6.75	$13.65
% Upside from Price Target	256.22% upside	66.18% upside	155.22% upside	162.65% upside	225.78% upside
Trade Information
Market Cap	$110.17 million	$110.41 million	$129.18 million	$107.66 million	$181.92 million
Beta	2.31	1.68	1.58	1.49	2.83
Average Volume	1,112,561	16,703,836	605,787	587,679	4,811,492
Sales & Book Value
Annual Revenue	$600,000.00	$22.11 million	$250,000.00	N/A	$90,000.00
Price / Sales	187.64	5.07	541.87	N/A	1,920.51
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.31 per share	$0.58 per share	$0.35 per share	$0.71 per share	$3.26 per share
Price / Book	1.78	1.30	12.31	N/A	1.29
Profitability
Net Income	$-44,670,000.00	$-29,310,000.00	$-10,020,000.00	$-72,180,000.00	$-32,940,000.00
EPS	($1.45)	($0.55)	($0.59)	($1.85)	($1.50)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-14,379.87%	-188.31%	N/A	N/A	N/A
Return on Equity (ROE)	-108.75%	-99.57%	-153.08%	-51.19%	-60.20%
Return on Assets (ROA)	-54.62%	-67.47%	-129.89%	-29.75%	-52.40%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.20%	0.05%	N/A	N/A	N/A
Current Ratio	8.97%	1.32%	7.88%	6.49%	6.54%
Quick Ratio	8.97%	1.16%	7.88%	6.49%	6.54%
Ownership Information
Institutional Ownership Percentage	72.25%	7.36%	7.68%	66.28%	25.99%
Insider Ownership Percentage	16.10%	5.90%	23.30%	12.00%	11.10%
Miscellaneous
Employees	56	131	3	11	26
Shares Outstanding	48.32 million	148.89 million	31.43 million	42.72 million	41.25 million
Next Earnings Date	5/6/2021 (Estimated)	5/17/2021 (Estimated)	6/8/2021 (Estimated)	5/3/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Zynerba Pharmaceuticals Inc. [ZYNE] Stock trading around $4.41 per share: What’s Next? dbtnews.com - April 22 at 10:08 AM
	Short Interest in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Decreases By 23.7% americanbankingnews.com - April 18 at 1:56 AM
	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological ... apnews.com - April 16 at 9:23 AM
	Zynerba Pharmaceuticals Inc (ZYNE) investing.com - April 15 at 1:39 PM
	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting finance.yahoo.com - April 15 at 8:38 AM
	Zynerba Pharmaceuticals, Inc. (ZYNE) investors to reap big returns again marketingsentinel.com - April 13 at 8:39 AM
	Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives Consensus Rating of "Buy" from Brokerages americanbankingnews.com - April 9 at 8:44 AM
	Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference finance.yahoo.com - April 6 at 7:51 AM
	-$0.25 Earnings Per Share Expected for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) This Quarter americanbankingnews.com - April 6 at 4:10 AM
	Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): The Stock for Success Over the Next Few Months marketingsentinel.com - March 29 at 3:39 PM
	Zynerba (ZYNE) Alert: Shareholder Class Action... benzinga.com - March 28 at 1:28 PM
	Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel finance.yahoo.com - March 28 at 8:28 AM
	Are Investors Keen On Selling Holdings In Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)? stocksregister.com - March 26 at 2:26 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? finance.yahoo.com - March 12 at 1:13 PM
	Zynerba: Q4 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - March 10 at 1:27 PM
	Zynerba: Q4 Earnings Snapshot thetelegraph.com - March 10 at 8:26 AM
	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights finance.yahoo.com - March 10 at 8:26 AM
	CBD Co. Zynerba, Investors Aim To Settle Drug Trial Claims law360.com - March 10 at 12:33 AM
	Global Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major Players marketwatch.com - March 5 at 2:35 PM
	Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference finance.yahoo.com - March 4 at 12:40 PM
	4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy? marketwatch.com - March 3 at 5:14 AM
	Marijuana as medicine: the other cannabinoid pharma players seekingalpha.com - February 8 at 8:36 AM
	ZYNE Stock Price Increases Over 20%: Why It Happened pulse2.com - February 3 at 7:05 PM
	GW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover Deal finance.yahoo.com - February 3 at 2:04 PM
	Analysts Offer Insights on Healthcare Companies: and Armata Pharmaceuticals (ARMP) smarteranalyst.com - February 1 at 8:59 AM

Date	Company	Brokerage	Action
4/13/2021	Otonomy	Piper Sandler	Boost Price Target
3/1/2021	Otonomy	HC Wainwright	Lower Price Target
11/22/2020	Otonomy	Oppenheimer	Initiated Coverage
8/17/2020	Otonomy	Cantor Fitzgerald	Reiterated Rating
5/29/2020	Otonomy	Craig Hallum	Initiated Coverage
3/5/2019	Otonomy	Piper Jaffray Companies	Reiterated Rating
8/14/2018	Otonomy	SunTrust Banks	Lower Price Target
1/22/2021	Adamis Pharmaceuticals	Maxim Group	Reiterated Rating
8/24/2020	Adamis Pharmaceuticals	Dawson James	Downgrade
8/19/2020	Adamis Pharmaceuticals	Raymond James	Reiterated Rating
7/23/2019	Adamis Pharmaceuticals	B. Riley	Upgrade
2/15/2021	Anixa Biosciences	Aegis	Reiterated Rating
9/11/2020	Minerva Neurosciences	William Blair	Reiterated Rating
7/1/2020	Minerva Neurosciences	JMP Securities	Reiterated Rating
6/1/2020	Minerva Neurosciences	BTIG Research	Lower Price Target
5/29/2020	Minerva Neurosciences	Jefferies Financial Group	Downgrade
12/2/2019	Minerva Neurosciences	Chardan Capital	Reiterated Rating
8/3/2018	Minerva Neurosciences	Citigroup	Boost Price Target
3/10/2021	Zynerba Pharmaceuticals	Roth Capital	Lower Price Target
2/5/2021	Zynerba Pharmaceuticals	Canaccord Genuity	Reiterated Rating
9/14/2020	Zynerba Pharmaceuticals	Needham & Company LLC	Reiterated Rating
6/29/2020	Zynerba Pharmaceuticals	LADENBURG THALM/SH SH	Reiterated Rating

(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources